Sunday, October 7, 2012

Fundamentals of Cancer Research


Life is possible through many different biological pathways. Cells alone have such complicated signaling cascades that researchers are finding new proteins and new interactions with old proteins constantly. Cancerous cells come about when those pathways are manipulated or mutated to promote cell growth and replication while inhibiting cell death. This article is a foundational review of some of the pathways cancers take advantage of. To summarize the article pathways start at the cell membrane/surface and are relayed until the signal can control gene expression in the nucleus. A couple of pathways the article touches on include the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways. Within these two pathways of cell growth/replication the cell has ways to inhibit the growth/replication by turning to self destruction/apoptosis. However, cancerous cells have mutations in those negative feedbacks. It was recently found that both of these pathways co-regulate many downstream targets involved in growth/replication regulation at the same time. Thusly, these two pathways must be inhibited at the same time to effectively stop cancerous growth. Drugs that inhibit mTOR production alone were thought to be promising at first until further studies found the inhibition to be counterproductive. When mTOR, which is produced by the activated Akt, is inhibited it turns on a secondary Akt activator to promote further Akt production and therefore further mTOR production. In essence the cell has a switch to reactivate mTOR through overproduction of Akt. The only sure thing was finding a way to inhibit mTOR, PI3K, and the secondary Akt activator. Classical chemotherapies tend to target systems much further down the cascade than these signals, such as actual DNA replication or cell division, and in doing so increase a cell’s tendency to move towards cancerous behavior by activating cell survivor mode pathways which trigger the two pathways mentioned above. The next exciting step in cancer treatment very well may be creating a single drug that can inhibit both of these pathways effectively and minimize toxicity. I will follow up with more recent publications.